Introduction: HIV-2 infection is endemic in West Africa and some European countries, namely Portugal. HIV-2 antiretroviral (ARV) treatment presents some restrains related to intrinsic resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) and fusion inhibitors, and poorer response to protease inhibitors (PI). Material and Methods: Retrospective observational study of a cohort of 135 infected HIV-2 patients, diagnosed between 1989 and 2008. Objectives: Evaluation of epidemiologic, clinical, immunologic and virologic progression, comparing to groups of patients (naïve vs ARV experienced); characterization of therapeutic, immunologic and virologic response. SPSS version 20.0 was used for statistical analysis. Results: The study included 135 patients: 41% (n 055) naïve and 59% (n 080) with ARV experience. The comparison between groups (naïve vs ARV) revealed: male prevalence 76% vs 50%; mean age 54.5 years vs 54.8 (p 00.90); main geographic origin Guiné Bissau (47% vs 44%) and Portugal (22% vs 33%); and transmission mainly acquired by heterosexual contact (87% vs 80%). Mean time since diagnosis was 14 vs 13 years (p 00.31); 2% vs 50% presented AIDS criteria at diagnosis (p B0.001) and 93% vs 38% registered TCD4350 cell/mm 3 at diagnosis (p B0.001). Immunological evolution showed no significant decline in naïve population (D 0(67 cell/mm 3 Á p00.18) and a significant recovery in ARV experienced (D 0'207 cell/mm 3 Á p B0.001). Global mortality rate found was 18% (6% vs 13% Á p00.122). Eighty patients initiated ARV: 84% presented a time interval of ARV exposure between 0Á5 years (42%) and 5Á10 years (42%). Fifty percent experienced 52 ARV regimens and the remaining 2 regimes. Considering the first ARV therapy: 56% initiated PI, 30% NTRI and 5% integrase inhibitor (II)-based regimens. Currently, 54 patients maintain regular follow-up and ARV therapy: 60% NTRI'PI; 37% NRTI'PI'II and 3% NRTI'II. TDF/FTC is the backbone in 56%. Most frequent PIs are LPV/r (54%), DRV/r (19%) and ATV/r (12%). Mean time of exposure to NRTI 03 years, PI07 years and II 02 years. Immunologic recovery was sustained for each of the ARV class considered (NRTI D0'144 cell/mm
